<DOC>
	<DOCNO>NCT00459745</DOCNO>
	<brief_summary>This multi-center , double blind , prospective , longitudinal , randomize , 12-week study 52-week open-label follow-up evaluate safety efficacy daily administration Pravastatin 40 mg Fenofibrate 160 mg Pravafen ( combination Pravastatin Fenofibrate 40/160 mg ) treatment combine hyperlipidemia . There open-label , 8-week , Selection Phase prior randomization patient stabilize Pravastatin 40 mg/day . Following Selection Phase , patient meet inclusion/exclusion criterion , randomize three arm , double blind , 12-week Efficacy Phase would receive either Pravastatin 40 mg Fenofibrate 160 mg Pravafen ( combination Pravastatin Fenofibrate 40/160 mg ) . The 12-week Efficacy Phase follow open-label , 52-week , Safety Phase patient receive Pravafen . After 8-week Selection Phase , patient still meet inclusion/exclusion criterion randomize 1:1:2 ratio Pravastatin 40 mg Fenofibrate 160 mg Pravafen ( combination Pravastatin Fenofibrate 40/160 mg ) 12 week . After completion 12-week double-blind phase study , patient n't change well , allow roll-over 52-week , open-label , follow-up portion study . During 52 week , open label , Safety Phase study , patient receive Pravafen ( combination Pravastatin Fenofibrate 40/160 mg ) . Patients evaluate baseline every three week thereafter throughout initial 12-week Efficacy Phase study . Patients roll-over 52-week , open-label , follow-up Safety Phase evaluate 12 , 24 , 36 52 week . Participation study 72 week .</brief_summary>
	<brief_title>A Study Evaluate Daily Pravastatin , Fenofibrate Pravafen Treatment Combined Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Patients meet criterion list may select enroll Selection Phase study : 1 . Male female patient 1875 year age , inclusive time dose history combine hyperlipidemia . 2 . High LDL cholesterol TG level per table hereunder : Prior treatment LDL Cholesterol TG Naïve treatment* &gt; 130 mg/dL ≥ 150 mg/dL ≤ 400 mg/dL Lipid Lowering Monotherapy &gt; 130 mg/dL ≥ 150 mg/dL ≤ 400 mg/dL Lipid Lowering Combination Therapy &gt; 110 mg/dL ≥ 150 mg/dL ≤ 400 mg/dL * A patient receive NO lipid lower therapy within 6 week prior Selection Visit , consider Naïve treatment . 3 . If patient female childbearing potential sexually active , acceptable birth control method must use ( abstinence , IUD , oral , transdermal , injectable implantable contraceptive , least 2 year postmenopausal , one year post hysterectomy , double barrier device and/or partner least one year post vasectomy ) , negative serum pregnancy test must obtain Selection Visit ( Visit 1 ) negative urine pregnancy test must obtain prior study drug administration Baseline Visit ( Visit 3 ) . 4 . Able comply study procedure . 5 . Patients provide write informed consent participate study indicate personal signature date patient consent form . At end Selection Phase , patient meet criterion list may select randomized Efficacy Phase study : 1 . Selected patient LDL Cholesterol ≥ 100 mg/dl and/or TG ≥ 150 mg/dl ≤ 400 mg/dl Week1 / Visit 2 take Pravastatin 40 mg/day Visit 1 . 2 . Patients still meet selection criterion , c , e list section 4.1 . 3 . Patients compliance ≥ 80 % 8week Pravastatin phase study . Patients exclude study one follow apply : 1 . Female childbearing potential pregnant and/or lactate and/or sexually active use acceptable method contraception 2 . History allergy contraindication : fenofibrate similar compound HMGCoA reductase inhibitor 3 . History uncontrolled unstable ; diabetes ( ( i.e. , diabetic nephropathy etc . ) , hepatic impairment/insufficiency , renal impairment/insufficiency ( i.e. , nephritis , polycystic kidney disease , acute chronic renal failure , endstage renal disease , GFR &lt; 60 ml/min , etc . ) , neurological , gastrointestinal ( ulcerative colitis , Barrett 's , etc . ) , gallbladder disease ( patient prior cholecystectomy allowed participate ) , psychiatric disease , sleep apnea clinically significant medical surgical history could affect safety patient hinder evaluation drug effect base Investigator Medical Monitor discretion 4 . Acute liver disease persistent elevation liver function test ( 2 time upper normal limit great ) 5 . Levels creatine phosphokinase ( CK ) 3 time upper normal limit great 6 . Change diuretic βblocker treatment hypertension within 30 day enrollment selection phase ( Visit 1 ) 7 . Positive personal history abuse follow : Alcohol ( per DSMIV criterion ) and/or Recreational drug ( per DSMIV criterion ) 8 . Usage follow medication ( patient must discontinue medication 5 halflives 30 day , whichever great prior study drug administration Visit 3 / Day 0 ) : Corticosteroids Immunosuppressants Macrolide antibiotic Azole antifungal agent , 9 . Recent use investigational drug . These drug must discontinue either 5 halflives 30 day whichever great prior Visit 1 10 . Hyperlipidemia type IIIaIVV 11 . LDL &lt; 100 mg/dL 12 . TG &lt; 150 mg/dL &gt; 400 mg/dL 13 . Uncontrolled primary hypothyroidism 14 . History acute myocardial infarction , stroke within last 6 month prior Visit 1 ; unstable angina clinically significant heart failure 15 . Uncontrolled hypertension , define SBP &gt; 160 mmHg DBP &gt; 100 mmHg antihypertensive medication 16 . Type 1 diabetes type 2 diabetes mellitus require insulin , diabetic patient poor control ( HbA1c level &gt; 8.5 % ) , abnormal renal function ( GFR &lt; 60 ml/mn ) renal disease likely lead renal dysfunction ) 17 . Use prohibit medication detailed concomitant medication section 18 . Non adherence American Heart Association Step II diet introduce Visit 1 19 . Presence condition illness , , opinion Principal Investigator , would interfere patient 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Fenofibrate</keyword>
	<keyword>LDL cholesterol</keyword>
	<keyword>HDL cholesterol</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Pravastatin</keyword>
	<keyword>Triglycerides</keyword>
</DOC>